Amyloid-Beta Induced CA1 Pyramidal Cell Loss in Young Adult Rats Is Alleviated by Systemic Treatment with FGL, a Neural Cell Adhesion Molecule-Derived Mimetic Peptide

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Corbett, Nicola J ^a   Gabbott, Paul L ^a   Klementiev, Boris ^b   Davies, Heather A ^a   Colyer, Frances M ^a   Novikova, Tatiana ^b   Stewart, Michael G ^a  

^a OPEN UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; FG LOOP; GLYCOGEN SYNTHASE KINASE 3BETA; NERVE CELL ADHESION MOLECULE; NEURON SPECIFIC NUCLEAR PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INACTIVATION; HEART RIGHT VENTRICLE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; IMMUNOCYTOCHEMISTRY; MALE; MEMORY; MEMORY DISORDER; MENTAL PERFORMANCE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PYRAMIDAL NERVE CELL; RAT; RECOGNITION; SOCIAL RECOGNITION MEMORY; STEREOLOGY; SYSTEMIC THERAPY;

EID: 84881247238     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071479     Document Type: Article

References (68)

1. Terry RD, Gonatas NK, Weiss M, (1964) Ultrastructural Studies in Alzheimer's Presenile Dementia. Am J Pathol 44: 269-297.
2. Mann DM, Yates PO, (1986) Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders. Hum Neurobiol 5: 147-158.
3. Masliah E, Terry RD, DeTeresa RM, Hansen LA, (1989) Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci Lett 103: 234-239.
4. Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS, (1981) Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 10: 184-192.
5. Broe M, Shepherd CE, Milward EA, Halliday GM, (2001) Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol 101: 616-624.
6. Hubbard BM, Anderson JM, (1985) Age-related variations in the neuron content of the cerebral cortex in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 11: 369-382.
7. Mann DM, Yates PO, Marcyniuk B, (1985) Some morphometric observations on the cerebral cortex and hippocampus in presenile Alzheimer's disease, senile dementia of Alzheimer type and Down's syndrome in middle age. J Neurol Sci 69: 139-159.
8. Giannakopoulos P, Hof PR, Kovari E, Vallet PG, Herrmann FR, et al. (1996) Distinct patterns of neuronal loss and Alzheimer's disease lesion distribution in elderly individuals older than 90 years. J Neuropathol Exp Neurol 55: 1210-1220.
9. Gomez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, et al. (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16: 4491-4500.
10. Arendt T, Bigl V, Arendt A, Tennstedt A, (1983) Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease. Acta Neuropathol 61: 101-108.
11. Fukutani Y, Cairns NJ, Rossor MN, Lantos PL, (1996) Purkinje cell loss and astrocytosis in the cerebellum in familial and sporadic Alzheimer's disease. Neurosci Lett 214: 33-36.
12. Brun A, Englund E, (1981) Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading. Histopathology 5: 549-564.
13. Mann DM, Yates PO, Marcyniuk B, (1985) Correlation between senile plaque and neurofibrillary tangle counts in cerebral cortex and neuronal counts in cortex and subcortical structures in Alzheimer's disease. Neurosci Lett 56: 51-55.
14. Hansen LA, DeTeresa R, Davies P, Terry RD, (1988) Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer's disease. Neurology 38: 48-54.
15. Elgh E, Lindqvist Astot A, Fagerlund M, Eriksson S, Olsson T, et al. (2006) Cognitive dysfunction, hippocampal atrophy and glucocorticoid feedback in Alzheimer's disease. Biol Psychiatry 59: 155-161.
16. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL, (1984) Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 225: 1168-1170.
17. Kerchner GA, Hess CP, Hammond-Rosenbluth KE, Xu D, Rabinovici GD, et al. (2010) Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI. Neurology 75: 1381-1387.
18. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ, (2007) Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68: 1501-1508.
19. West MJ, Kawas CH, Martin LJ, Troncoso JC, (2000) The CA1 region of the human hippocampus is a hot spot in Alzheimer's disease. Ann N Y Acad Sci 908: 255-259.
20. Stewart MG, (2008) Colostrinin: a naturally occurring compound derived from mammalian colostrum with efficacy in treatment of neurodegenerative diseases, including Alzheimer's. Expert Opin Pharmacother 9: 2553-2559.
21. Klementiev B, Novikova T, Novitskaya V, Walmod PS, Dmytriyeva O, et al. (2007) A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35. Neuroscience 145: 209-224.
22. Kiselyov VV, Skladchikova G, Hinsby AM, Jensen PH, Kulahin N, et al. (2003) Structural basis for a direct interaction between FGFR1 and NCAM and evidence for a regulatory role of ATP. Structure 11: 691-701.
23. Christensen C, Lauridsen JB, Berezin V, Bock E, Kiselyov VV, (2006) The neural cell adhesion molecule binds to fibroblast growth factor receptor 2. FEBS Lett 580: 3386-3390.
24. Neiiendam JL, Kohler LB, Christensen C, Li S, Pedersen MV, et al. (2004) An NCAM-derived FGF-receptor agonist, the FGL-peptide, induces neurite outgrowth and neuronal survival in primary rat neurons. J Neurochem 91: 920-935.
25. Borcel E, Perez-Alvarez L, Herrero AI, Brionne T, Varea E, et al. (2008) Chronic stress in adulthood followed by intermittent stress impairs spatial memory and the survival of newborn hippocampal cells in aging animals: prevention by FGL, a peptide mimetic of neural cell adhesion molecule. Behav Pharmacol 19: 41-49.
26. Downer EJ, Cowley TR, Lyons A, Mills KH, Berezin V, et al. (2010) A novel anti-inflammatory role of NCAM-derived mimetic peptide, FGL. Neurobiol Aging 31: 118-128.
27. Popov VI, Medvedev NI, Kraev IV, Gabbott PL, Davies HA, et al. (2008) A cell adhesion molecule mimetic, FGL peptide, induces alterations in synapse and dendritic spine structure in the dentate gyrus of aged rats: a three-dimensional ultrastructural study. Eur J Neurosci 27: 301-314.
28. Skibo GG, Lushnikova IV, Voronin KY, Dmitrieva O, Novikova T, et al. (2005) A synthetic NCAM-derived peptide, FGL, protects hippocampal neurons from ischemic insult both in vitro and in vivo. Eur J Neurosci 22: 1589-1596.
29. Ojo B, Rezaie P, Gabbott PL, Cowely TR, Medvedev NI, et al. (2011) A neural cell adhesion molecule-derived peptide, FGL, attenuates glial cell activation in the aged hippocampus. Exp Neurol 232: 318-328.
30. Ojo B, Rezaie P, Gabbott PL, Davies H, Colyer F, et al. (2012) Age-related changes in the hippocampus (loss of synaptophysin and glial-synaptic interaction) are modified by systemic treatment with an NCAM-derived peptide, FGL. Brain Behav Immun 26: 778-788.
31. Cambon K, Hansen SM, Venero C, Herrero AI, Skibo G, et al. (2004) A synthetic neural cell adhesion molecule mimetic peptide promotes synaptogenesis, enhances presynaptic function, and facilitates memory consolidation. J Neurosci 24: 4197-4204.
32. Secher T, Novitskaia V, Berezin V, Bock E, Glenthoj B, et al. (2006) A neural cell adhesion molecule-derived fibroblast growth factor receptor agonist, the FGL-peptide, promotes early postnatal sensorimotor development and enhances social memory retention. Neuroscience 141: 1289-1299.
33. Hernandez F, de Barreda EG, Fuster-Matanzo A, Goni-Oliver P, Lucas JJ, et al. (2009) The role of GSK3 in Alzheimer disease. Brain Res Bull 80: 248-250.
34. Arancibia S, Silhol M, Mouliere F, Meffre J, Hollinger I, et al. (2008) Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol Dis 31: 316-326.
35. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, et al. (1995) Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 64: 253-265.
36. Stepanichev MY, Zdobnova IM, Zarubenko, II, Lazareva NA, Gulyaeva NV, (2006) Studies of the effects of central administration of beta-amyloid peptide (25-35): pathomorphological changes in the Hippocampus and impairment of spatial memory. Neurosci Behav Physiol 36: 101-106.
37. Suh EC, Jung YJ, Kim YA, Park EM, Lee KE, (2008) A beta 25-35 induces presynaptic changes in organotypic hippocampal slice cultures. Neurotoxicology 29: 691-699.
38. Takashima A, Noguchi K, Michel G, Mercken M, Hoshi M, et al. (1996) Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci Lett 203: 33-36.
39. Delobette S, Privat A, Maurice T, (1997) In vitro aggregation facilities beta-amyloid peptide-(25-35)-induced amnesia in the rat. Eur J Pharmacol 319: 1-4.
40. Holscher C, Gengler S, Gault VA, Harriott P, Mallot HA, (2007) Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur J Pharmacol 561: 85-90.
41. Olariu A, Tran MH, Yamada K, Mizuno M, Hefco V, et al. (2001) Memory deficits and increased emotionality induced by beta-amyloid (25-35) are correlated with the reduced acetylcholine release and altered phorbol dibutyrate binding in the hippocampus. J Neural Transm 108: 1065-1079.
42. Knafo S, Alonso-Nanclares L, Gonzalez-Soriano J, Merino-Serrais P, Fernaud-Espinosa I, et al. (2009) Widespread changes in dendritic spines in a model of Alzheimer's disease. Cereb Cortex 19: 586-592.
43. Kogan JH, Frankland PW, Silva AJ, (2000) Long-term memory underlying hippocampus-dependent social recognition in mice. Hippocampus 10: 47-56.
44. Paxinos G, Watson C (1998) The Rat Brain in Stereotaxic Coordinates. Orlando, USA: Academic Press.
45. Fiala JC, Harris KM, (2001) Extending unbiased stereology of brain ultrastructure to three-dimensional volumes. J Am Med Inform Assoc 8: 1-16.
46. West MJ, Slomianka L, Gundersen HJ, (1991) Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231: 482-497.
47. Gundersen HJ, (1986) Stereology of arbitrary particles. A review of unbiased number and size estimators and the presentation of some new ones, in memory of William R. Thompson. J Microsc 143: 3-45.
48. Slomianka L, West MJ, (2005) Estimators of the precision of stereological estimates: an example based on the CA1 pyramidal cell layer of rats. Neuroscience 136: 757-767.
49. Weibel ER, (1981) Stereological Methods. Vol. 1. Practical Methods for Biological Morphometry. By Ewald R. Weibel. J Microsc 121: 131-132.
50. Kong LN, Zuo PP, Mu L, Liu YY, Yang N, (2005) Gene expression profile of amyloid beta protein-injected mouse model for Alzheimer disease. Acta Pharmacol Sin 26: 666-672.
51. Secher T, Berezin V, Bock E, Glenthoj B, (2009) Effect of an NCAM mimetic peptide FGL on impairment in spatial learning and memory after neonatal phencyclidine treatment in rats. Behav Brain Res 199: 288-297.
52. Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, et al. (1996) Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 119 (Pt 6): 2001-2007.
53. Stoub TR, deToledo-Morrell L, Stebbins GT, Leurgans S, Bennett DA, et al. (2006) Hippocampal disconnection contributes to memory dysfunction in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A 103: 10041-10045.
54. Coleman PD, Flood DG, (1987) Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging 8: 521-545.
55. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, et al. (2001) Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 58: 1395-1402.
56. Rossler M, Zarski R, Bohl J, Ohm TG, (2002) Stage-dependent and sector-specific neuronal loss in hippocampus during Alzheimer's disease. Acta Neuropathol 103: 363-369.
57. West MJ, Coleman PD, Flood DG, Troncoso JC, (1994) Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 344: 769-772.
58. Andersen P (2007) The hippocampus book. New York; Oxford: Oxford University Press. xx, 832 p. p.
59. Ojo B, Gabbott PL, Rezaie P, Corbett N, Medvedev NI, et al. (2013) An NCAM mimetic, FGL, alters hippocampal cellular morphometry in young adult (4 month-old) rats. Neurochem Res 38: 1208-1218.
60. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, et al. (2004) Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 101: 2173-2178.
61. Takashima A, Honda T, Yasutake K, Michel G, Murayama O, et al. (1998) Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res 31: 317-323.
62. Beurel E, Jope RS, (2006) The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 79: 173-189.
63. Hu S, Begum AN, Jones MR, Oh MS, Beech WK, et al. (2009) GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 33: 193-206.
64. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, et al. (2007) Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 27: 1981-1991.
65. Pap M, Cooper GM, (1998) Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 273: 19929-19932.
66. Song L, Zhou T, Jope RS, (2004) Lithium facilitates apoptotic signaling induced by activation of the Fas death domain-containing receptor. BMC Neurosci 5: 20.
67. Engel T, Hernandez F, Avila J, Lucas JJ, (2006) Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 26: 5083-5090.
68. Gomez-Sintes R, Hernandez F, Bortolozzi A, Artigas F, Avila J, et al. (2007) Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J 26: 2743-2754.